The influence factors of S100A12 and its correlation with carotid artery atherosclerosis in hemodialysis patients

doi:10.3969/j.issn.1673-8640.2014.09.014

Abstract

Abstract: Objective To investigate the influence factors of plasma S100 calcium binding protein A12 (S100A12) level in hemodialysis patients and the correlation between S100A12 and carotid artery atherosclerosis. Methods A total of 150 hemodialysis patients and 100 healthy subjects were enrolled. The white blood cell counts, alanine transaminase(ALT), aspartate aminotransferase (AST), albumin(Alb), creatinine(Cr), urea, triglyceride (TG), total cholesterol(TC), blood glucose, glycosylated hemoglobin and S100A12 concentrations of hemodialysis patients were determined and compared with those of healthy subjects. Carotid intima-media thickness (CIMT) was measured by high-resolution B-mode ultrasonography in hemodialysis patients and also compared with that in healthy subjects. The correlation between S100A12 and CIMT was analyzed by Person correlation analysis. The multivariate regression analysis was used to analyze the influence factors of S100A12 concentration. Results The plasma S100A12 concentration was higher in hemodialysis patients than in healthy subjects (P<0.05). Significant positive correlation was recorded between S100A12 and CIMT (r=0.4, P<0.01). Multivariate regression analysis identified high white blood cell counts as a positive plasma independent determinant and low TC and low Alb as negative independent determinants of plasma S100A12 concentration. Conclusions S100A12 is related to carotid artery atherosclerosis. The white blood cell counts, TC and Alb are associated with S100A12 concentration.

Key words: S100 calcium binding protein A12, Carotid intima-media thickness, Renal failure, Advanced stage, Hemodialysis, Carotid artery atherosclerosis

CLC Number:

R446.1

GUO Huan, LU Bin. The influence factors of S100A12 and its correlation with carotid artery atherosclerosis in hemodialysis patients[J]. , 2014, 29(9): 930-934.

References

[1] Collins AJ.Cardiovascular mortality in end-stage renal disease[J]. Am J Med Sci, 2003,325(4): 163-167.
[2] Nasri H, Baradaran A, Naderi AS, et al. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis[J]. Acta Med Austriaca, 2004,31(3): 67-72.
[3] Goyette J, Geczy CL. Inflammation-associated S100 proteins:new mechanisms that regulate function [J]. Amino Acids,2011,41(4):821-842.
[4] Perera C, McNeil HP, Geczy CL. S100 calgranulins in inflammatory arthritis [J]. Immunol Cell Biol, 2010,88(1):41-49.
[5] 郑海涵,吴正祥,杨枫,等.炎症性肠病中S100A12抗体的表达及临床意义[J].安徽医科大学学报,2012,47(3):295-298.
[6] Gawdzik J, Mathew L, Kim G, et al. Vascular remodeling and arterial calcification are directly mediated by S100A12(EN-RAGE) in chronic kidney disease [J]. Am J Nephrol, 2011,33(3):250-259.
[7] Uchiyama-Tanaka Y, Mori Y, Kosaki A, et al. Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease[J]. Ther Apher Dial, 2008, 12(1): 28-32.
[8] Brzosko S, Lebkowska U, Malyszko J, et al. Intima media thickness of common carotid arteries is associated with traditional risk factors and presence of ischaemic heart disease in hemodialysis patients[J]. Physiol Res, 2005, 54(5): 497-504.
[9] Lee D, Lee KH, Park H,et al. The effect of soluble RAGE on inhibition of angiotensin Ⅱ-mediated atherosclerosis in apolipoprotein E deficient mice[J].PLoS One, 2013, 8(8): e69669.
[10] Nakashima A, Carrero JJ, Qureshi AR, et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients[J]. Clin J Am Soc Nephrol, 2010, 5(12): 2213-2219.
[11] Shiotsu Y, Mori Y, Nishimura M, et al. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients[J]. Clin J Am Soc Nephrol, 2011, 6(4): 718-723.
[12] Zhao P,Wu M,Yu H,et al. Serum S100A12 levels are correlated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus[J]. J Investig Med,2013,61(5):861-866.
[13] Wu T, McGrath KC, Death AK. Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers[J]. Vasc Health Risk Manag, 2005, 1(4): 309-316.
[14] Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection[J]. J Am Soc Nephrol, 2007, 18(3): 896-903.
[15] Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system[J]. Circulation, 2007, 116(1): 85-97.
[16] Kalantar-Zadeh K, Stenvinkel P, Pillon L, et al. Inflammation and nutrition in renal insufficiency[J]. Adv Ren Replace Ther, 2003, 10(3): 155-169.
[17] Allan PL, Mowbray PI, Lee AJ, et al. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study[J]. Stroke, 1997, 28(2): 348-353.